· Published by Health Canada · Official notice
This is duplicated text of a letter from AstraZeneca Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
February 13, 2012
Subject: Serious risks of QTc prolongation, Torsade de Pointes, and sudden death for CAPRELSA (vandetanib)
Dear Health Care Professional,
AstraZeneca Canada Inc., in consultation with Health Canada, would like to inform you of important information regarding the safety of CAPRELSA® (vandetanib). Health Canada has recently approved CAPRELSA as a monotherapy for the treatment of symptomatic or progressive medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease. CAPRELSA use should be carefully considered based on a risk-benefit assessment in patients with indolent, asymptomatic or slowly progressive disease because of the significant treatment-related risks.
In addition to QTc interval prolongation, Torsade de Pointes, sudden death, rash and other skin reactions, diarrhea, hypertension and vision abnormalities have also been reported in patients taking CAPRELSA. For a complete list of adverse events associated with CAPRELSA, please see the CAPRELSA Product Monograph.
Prior to prescribing CAPRELSA, physicians are required to:
Should you require paper-based training materials, please contact AstraZeneca Canada's Medical Information department at 1-800-668-6000 (English) and/or 1-800-461-3787 (French).
Upon certification in the CAPRELSA Restricted Distribution Program:
Adverse Events
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious QTc prolongation, Torsade de Pointes, sudden death, or other serious or unexpected adverse reactions in patients receiving CAPRELSA should be reported to AstraZeneca Canada or Health Canada.
AstraZeneca Canada Inc.
1004 Middlegate Road
Mississauga, Ontario
Canada L4Y 1M4
Telephone: 1-877-404-8277
An Adverse Event form may be accessed at the Restricted Distribution Program Web site; please fax the completed form to 1-800-267-5743.
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Bureau of Metabolism, Oncology and Reproductive Sciences
E-mail: BMORS_Enquiries@hc-sc.gc.ca
Telephone: 613-941-3171
Fax: 613-941-1365
To change your mailing address or fax number, contact the Market Authorization Holder (AstraZeneca Canada Inc.).
Should you have any questions about CAPRELSA or the Restricted Distribution Program, please do not hesitate to contact AstraZeneca Medical Information at 1-800-668-6000 (English) and/or 1-800-461-3787 (French).
For questions on prescriber certification or the process to prescribe CAPRELSA, please contact the specialty pharmacy at 1-855-212-3922. All forms required for prescribing CAPRELSA can be accessed at the Restricted Distribution Program Web site and faxed to the specialty pharmacy at 1-855-212-7871.
original signed by
Dr. Neil Maresky, M.B., B.Ch.
Vice President, Scientific Affairs
AstraZeneca Canada Inc.
CAPRELSA® and the AstraZeneca logo are registered trademarks of the AstraZeneca group of companies.